论文部分内容阅读
目的探讨肺癌患者组织中程序性死亡配体-1(PD-L1)及血管内皮生长因子(VEGF)表达水平与肺癌术后化疗效果及肿瘤预后的关系。方法选取2013年9月-2015年9月在本院手术治疗的肺癌患者90例,收集患者肺癌组织,采用SP法检测患者肺癌组织中PD-L1及VEGF表达水平,分析二者表达水平与患者化疗效果的关系,并采用Logistic回归分析探讨PD-L1、VEGF表达与肺癌患者临床预后的关系。结果 90例患者中CR 20例,PR 39例,SD 12例,PD 15例,RR 65.6%;死亡4例;VEGF及PD-L1表达为强阳性和阳性的患者化疗有效人数均少于VEGF及PDL1表达为阴性的患者,差异有统计学意义(P<0.05);肿瘤分期、VEGF阳性、PD-L1阳性是肺癌患者死亡、转移或复发的独立危险因素。结论 PD-L1和VEGF阳性表达是肺癌患者术后新辅助化疗效果差、预后差的重要危险因素。
Objective To investigate the relationship between the expression of PD-L1 and VEGF and the postoperative chemotherapeutic effect and tumor prognosis in patients with lung cancer. Methods Ninety lung cancer patients undergoing surgery in our hospital from September 2013 to September 2015 were selected. The lung cancer tissues were collected. The expression of PD-L1 and VEGF in lung cancer tissues were detected by SP method. The relationship between the expression of PD-L1 and VEGF and the clinical prognosis of patients with lung cancer was analyzed by Logistic regression analysis. Results Among the 90 patients, there were 20 cases of CR, 39 cases of PR, 12 cases of SD, 15 cases of PD, and 65.6% RR; 4 cases died. The patients with strong positive and positive VEGF and PD-L1 expression had less effective chemotherapy than VEGF and The difference was statistically significant (P <0.05). The tumor staging, VEGF positive and PD-L1 positive were independent risk factors of death, metastasis or recurrence in patients with lung cancer. Conclusions The positive expression of PD-L1 and VEGF is an important risk factor for poor prognosis and poor prognosis in patients with lung cancer after neoadjuvant chemotherapy.